- Visibility 665 Views
- Downloads 701 Downloads
- Permissions
- DOI 10.18231/j.ijpo.2025.043
-
CrossMark
Comprehensive management of multiple endocrine neoplasia Type 2A (MEN2A): A multidisciplinary approach
- Author Details:
-
Neelima Gupta
-
Nimisha Srivastava
-
Jyoti Verma *
-
Pranjal Srivastava
Jyoti Verma *
Background: Multiple Endocrine Neoplasia Type 2A (MEN2A) is an autosomal dominant disorder characterized by medullary thyroid carcinoma (MTC), pheochromocytomas, and hyperparathyroidism. Early identification through genetic testing for RET proto-oncogene mutations and appropriate surgical interventions, such as prophylactic thyroidectomy, are crucial for optimal patient outcomes.
Case Description: A 42-year-old male presented with episodic hypertension and palpitations. Imaging studies, including computed tomography (CT) and ultrasound, revealed bilateral adrenal masses and thyroid nodules. Genetic analysis identified a mutation in the RET proto-oncogene, confirming a diagnosis of MEN2A. The patient underwent bilateral adrenalectomy and total thyroidectomy. Histopathological examination confirmed bilateral pheochromocytomas and MTC. Postoperative management included monitoring for hyperparathyroidism, a component of MEN2A, through regular assessments of serum calcium and parathyroid hormone levels.
Conclusion: This case underscores the importance of comprehensive evaluation in patients with endocrine tumours, including genetic testing for MEN2A. Early diagnosis and tailored surgical management are vital to prevent complications associated with this syndrome. Recognizing the constellation of symptoms associated with MEN2A allows for timely intervention, reducing morbidity and mortality. Genetic counselling and regular follow-up are essential components of patient care in hereditary endocrine neoplasia.
Keywords: Multiple endocrine neoplasia type 2A (MEN2A), Medullary thyroid carcinoma (MTC), Pheochromocytoma, Primary hyperparathyroidism.
References
- Kamilaris CDC, Stratakis CA. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis. Front Endocrinol (Lausanne). 2019;10:339.
- Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Gozzini A, Luzi E, et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis. 2006;2;1:38.
- Yasir M, Mulji NJ, Kasi A. Multiple Endocrine Neoplasias Type 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Jan 21]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK519054/
- Gupta PK, Marwaha B. Pheochromocytoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Jan 21]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK589700/
- Niranjan G, Prasad P, Gupta N, Agrawal V, Mishra A, Jain N, et al. Characteristics of Bilateral Adrenal Lesions: Experience from an Indian Tertiary Care Centre. Indian J Endocrinol Metab. 2024;28(3):273–8.
- Ungureanu S, Şipitco N, Alexa Z, Gonţa V, Bujac M, Parnov M, et al. MEN 2A syndrome – Multiple endocrine neoplasia with autosomal dominant transmission. Int J Surg Case Rep. 2020;73:141–5.
- Alevizaki M. Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe. Thyroid Res. 2013;6 Suppl 1(Suppl 1):S10.
- Paun D, Tilici D, Paun S, Mirica A. Prospective Genetic Screening in Multiple Endocrine Neoplasia Syndromes. Children (Basel). 2024;11(8):1012.
- Miyashita H, Yuen T. Parathyroid Gland Diseases. In: Zaidi M, editor. Encyclopedia of Bone Biology [Internet]. Oxford: Academic Press; 2020 [cited 2025 Jan 21]. p. 65–74.
- Walczyk A, Zgubieński K, Chmielewski G, Hińcza-Nowak K, Kowalik A, Jaskulski J, et al. Late-Onset Medullary Thyroid Cancer in a Patient with a Germline RET Codon C634R Mutation. Diagnostics (Basel). 2021;11(8):1448.
- Eng C, Plitt G. Multiple Endocrine Neoplasia Type 2. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2025 Jan 21]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/
- Schreinemakers JMJ, Zonnenberg BA, Höppener JWM, Hes FJ, Borel Rinkes IHM, Lips CJM. A patient with bilateral pheochromocytoma as part of a Von Hippel-Lindau (VHL) syndrome type 2C. World J Surg Oncol. 2007 Oct 8;5:112.
- Efared B, Atsame-Ebang G, Tahirou S, Mazaz K, Hammas N, El Fatemi H, Chbani L. Bilateral pheochromocytoma with ganglioneuroma component associated with multiple neuroendocrine neoplasia type 2A: a case report. J Med Case Rep. 2017;11(1):208.
- Cerny JC, Jackson CE, Talpos GB, Yott JB, Lee MW. Pheochromocytoma in multiple endocrine neoplasia type II: an Gupta et al. / Indian Journal of Pathology and Oncology 2025;12(2):212–217 217 example of the two-hit theory of neoplasia. Surgery. 1982;92(5):849–52.
- de Groot JW, Links TP, Hofstra RMW, Plukker JTM. An Introduction to Managing Medullary Thyroid Cancer. Hered Cancer Clin Pract. 2006;4(3):115–25.
- Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460–84.
- Giusti F, Marini F, Brandi ML. Multiple Endocrine Neoplasia Type
- In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2025 Jan 21]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1538/
- O’Riordain DS, O’Brien T, Grant CS, Weaver A, Gharib H, van Heerden JA. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery. 1993;114(6):1031–7.
- Lairmore TC, Piersall LD, DeBenedetti MK, Dilley WG, Mutch MG, Whelan AJ, et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg. 2004;239(5):637–45.
- Boukhannous I, Chennoufi M, Mokhtari M, El Moudane A, Barki A. Management of bilateral adrenal myelolipoma without endocrine disorder: About a rare case report. Urol Case Rep. 2021;39:101755.